1. ABBV-085 is a novel antibody–drug conjugate (ADC) that targets LRRC15 in the tumor microenvironment. (December 2016) Authors: Purcell, J.; Hickson, J.; Tanlimco, S.; Fox, M.; Chao, D.; Hsi, E.; Sho, M.; Powers, R.; Foster-Duke, K.; McGonigal, T.; Uziel, T.; Kumar, S.; Samayoa, J.; Longenecker, K.; Lai, D.; Hollenbaugh, D.; Afar, D.; Iyer, S.; Morgan-Lappe, S.; Gish, K. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S10 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗